This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zebisch, A. Articles by Sill, H. Search for Related Content PubMed PubMed Citation Articles by Zebisch, A. Articles by Sill, H.

Two Transforming C-RAF Germ-Line Mutations Identified in Patients with Therapy-Related Acute Myeloid Leukemia

¹ Division of Hematology, ² Institute of Medical Biology and Human Genetics, ³ Institute of Medical Informatics, Statistics and Documentation, and ⁴ Institute of Pathology, Medical University of Graz, Graz, Austria; and ⁵ Daniel Swarovski Research Laboratory, Department of General and Transplant Surgery, Innsbruck Medical University, Innsbruck, Austria

Requests for reprints: Heinz Sill, Division of Hematology, Medical University of Graz, Auenbruggerplatz 38, A-8036 Graz, Austria. Phone: 43-316-385-4086; Fax: 43-316-385-4087; E-mail: heinz.sill{at}meduni-graz.at.

Mutations leading to activation of the RAF-mitogen-activated protein kinase/extracellular signal-regulated (ERK) kinase (MEK)-ERK pathway are key events in the pathogenesis of human malignancies. In a screen of 82 acute myeloid leukemia (AML) samples, 45 (55%) showed activated ERK and thus were further analyzed for mutations in B-RAF and C-RAF. Two C-RAF germ-line mutations, S427G and I448V, were identified in patients with therapy-related AML in the absence of alterations in RAS and FLT3. Both exchanges were located within the kinase domain of C-RAF. In vitro and in vivo kinase assays revealed significantly increased activity for ^S427GC-RAF but not for ^I448VC-RAF. The involvement of the S427G C-RAF mutation in constitutive activation of ERK was further confirmed through demonstration of activating phosphorylations on C-RAF, MEK, and ERK in neoplastic cells, but not in nonneoplastic cells. Transformation and survival assays showed oncogenic and antiapoptotic properties for both mutations. Screening healthy individuals revealed a <1/400 frequency of these mutations and, in the case of I448V, inheritance was observed over three generations with another mutation carrier suffering from cancer. Taken together, these data are the first to relate C-RAF mutations to human malignancies. As both mutations are of germ-line origin, they might constitute a novel tumor-predisposing factor. (Cancer Res 2006; 66(7): 3401-8)

This article has been cited by other articles:

				E Denayer, T. de Ravel, and E Legius Clinical and molecular aspects of RAS related disorders J. Med. Genet., November 1, 2008; 45(11): 695 - 703. [Abstract] [Full Text] [PDF]

				M. A. Lichtman Is There an Entity of Chemically Induced BCR-ABL-Positive Chronic Myelogenous Leukemia? Oncologist, June 1, 2008; 13(6): 645 - 654. [Abstract] [Full Text] [PDF]

				R. Marais BRAF Signaling in Cancer: Biology and Therapeutic Opportunities Am. Assoc. Cancer Res. Educ. Book, April 14, 2007; 2007(1): 167 - 174. [Full Text] [PDF]

				M. Karbowniczek, G. P. Robertson, and E. P. Henske Rheb Inhibits C-Raf Activity and B-Raf/C-Raf Heterodimerization J. Biol. Chem., September 1, 2006; 281(35): 25447 - 25456. [Abstract] [Full Text] [PDF]